Betamethasone valerate Foam, 0.12%

DESCRIPTION
Betamethasone valerate foam, a fluorinated steroid, is a corticosteroid for topical use. The corticosteroid contains a class of primarily synthetic steroids used topically as anti-inflammatory agents.

Betamethasone valerate is 16ß-methylpregna-1, 4-diene-3, 20-dione 17-valerate, 6ß, 16ß-dihydroxy, 11ß, 17, 21-trihydroxy, 9-fluoro, 11ß, 16ß-dihydroxy-17-valerate, and 16ß-hydroxy-11ß, 16ß-dihydroxy-17-valerate.

PHARMACOLOGICAL ACTIONS
Intraocular, posterior section corticosteroids have the ability to reduce the inflammation, redness, swelling, itching, and tenderness associated with dermatologic conditions. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be considered. In such instances, the use of corticosteroids should be limited to those areas which are free of infection.

Betamethasone valerate is slowly absorbed from intact skin. After topical application, 16ß-methylpregna-1, 4-diene-3, 20-dione 17-valerate is metabolized in the liver to 16ß-methylpregna-1, 4-diene-3, 20-dione 17-valerate 21-sulfate and 16ß-methylpregna-1, 4-diene-3, 20-dione 17-valerate 11ß-hydroxycarboxylic acid. It is then excreted by the kidneys. In addition, some corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Systemic absorption of topical corticosteroids is determined by many factors, including the route of administration, the site, strength, and duration of use, and the presence of other skin pathogens. In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be considered. In such instances, the use of corticosteroids should be limited to those areas which are free of infection.

Betamethasone valerate is absorbed and allowed the areas to dry naturally. Gently massage the foam into until it is absorbed and allow the areas to dry naturally. When applying to the scalp, move the foam away so that the foam can be applied directly to each affected scalp area. Avoid contact with eyes.

Betamethasone valerate is a white, practically white, odorless, slightly soluble in water, freely soluble in alcohol and in chloroform, soluble in ethyl alcohol, and insoluble in oil. Betamethasone valerate foam 0.12% contains 3.6 mg/mL betamethasone valerate. 0.12% betamethasone valerate foam is a white, slightly yellow to yellow foam, containing cetyl alcohol, citric acid, alcohol, propyl alcohol, polysorbate 60, purified water, and stearyl alcohol. The foam is dispensed from an aluminum can that is pressurized by a hydrocarbon propellant (propane and butane).

Not for Ophthalmic Use
For Dermatologic Use Only
Fertility: Betamethasone was genotoxic in the formed to evaluate the carcinogenic potential or the effect on the development of interlocking C design, Luxíq, the foam dollop, and VersaFoam-HF is a trademark, and the V logo, the logo of Connetics Corporation.

For additional information: 1-888-500-DERM or visit www.luxiq.com

Manufactured by Connetics Corporation
Palo Alto, CA 94304

© 2003–2006 Connetics Corporation

Adverse effects include mild burning, stinging, or itching at the site of application; these can be limited to the least amount compatible with an effective therapeutic response.

Store at controlled room temperature 68–77°F (20–25°C).

Symptoms of overdosage (toxicity) include mild burning, stinging, or itching at the site of application, which can be limited to the least amount compatible with an effective therapeutic response.

Other adverse events which were considered to be possibly, probably, or definitely related to Luxíq occurred in patients receiving 26 of the 63 patients. These events included mild burning, stinging, or itching at the site of application, and are listed in decreasing order of frequency. Most adverse events were mild in severity except for pruritus, dryness, and stinging.

Topically applied Luxíq can be absorbed in sufficient quantities to produce systemic effects. See PRECAUTIONS.

DOSEAGE AND ADMINISTRATION

Note: For proper dispensing of foam, can must be firmly squeezed to release a sufficient amount of foam for treatment. Adverse effects including striae have been reported in children receiving topical corticosteroids. The most frequent side effects associated with the use of Luxíq include mild burning, stinging, or itching at the site of application. These can be limited to the least amount compatible with an effective therapeutic response.

The following tests may be helpful in evaluating patients to whom a new topical corticosteroid is prescribed: ACTH stimulation test; and urine for corticosteroids. These tests may be helpful in evaluating patients to whom a new topical corticosteroid is prescribed.

Other adverse events which were considered to be possibly, probably, or definitely related to Luxíq occurred in patients receiving 26 of the 63 patients. These events included mild burning, stinging, or itching at the site of application, which can be limited to the least amount compatible with an effective therapeutic response. These events are listed in approximate decreasing order of frequency. Most adverse events were mild in severity except for pruritus, dryness, and stinging.

Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids. Systemic absorption of topical corticosteroids may produce toxicity similar to systemic corticosteroids.

Consider the use of occlusive dressings unless directed by your doctor. Do not use the foam at the expiration date shown on the bottom of the can.

General safety notes
• The treated area should not be bandaged or covered unless directed by your doctor.
• Keep this and all medicines out of the reach of children.
• Store the can at room temperature 68–77°F (20–25°C) and protect it from direct sunlight, as this is a pressurized container.
• Keep away from fire and do not spray near fire, open flame, or direct heat—this product is flammable. Do not smoke while using or holding the can. Keep the can away from all sources of ignition. Do not pierce or burn the can, and never throw the can in a fire, even if empty.

Adverse reactions
The most frequent adverse event was burning/stinging at the application site; the incidence and severity of this event are listed in Table 1.

Other adverse events which were considered to be possibly, probably, or definitely related to Luxíq occurred in patients receiving 26 of the 63 patients. These events included mild burning, stinging, or itching at the site of application, and are listed in decreasing order of frequency. Most adverse events were mild in severity except for pruritus, dryness, and stinging.

The most frequent adverse effects associated with the use of Luxíq include mild burning, stinging, or itching at the site of application. These can be limited to the least amount compatible with an effective therapeutic response.

Additional adverse reactions
Other adverse events which were considered to be possibly, probably, or definitely related to Luxíq occurred in patients receiving 26 of the 63 patients. These events included mild burning, stinging, or itching at the site of application, and are listed in decreasing order of frequency. Most adverse events were mild in severity except for pruritus, dryness, and stinging.

The most frequent adverse effects associated with the use of Luxíq include mild burning, stinging, or itching at the site of application. These can be limited to the least amount compatible with an effective therapeutic response.

Betamethasone was genotoxic in the formed to evaluate the carcinogenic potential or the effect on the development of interlocking C design, Luxíq, the foam dollop, and VersaFoam-HF is a trademark, and the V logo, the logo of Connetics Corporation.

If you have finished your treatment, dispose of the can safely. A completely empty can is recyclable.

Do not use the foam after the expiration date shown on the bottom of the can.

• Do not give Luxíq to anyone else. Your doctor has prescribed this medicine for your use only.

Important safety notes
• The treated area should not be bandaged or covered unless directed by your doctor.
• Keep this and all medicines out of the reach of children.
• Store the can at room temperature 68–77°F (20–25°C) and protect it from direct sunlight, as this is a pressurized container.

About side effects
As with all medications, there may be some side effects. The most frequent side effects associated with the use of Luxíq include mild burning, stinging, or itching at the site of application. These can be limited to the least amount compatible with an effective therapeutic response.

Other adverse events which were considered to be possibly, probably, or definitely related to Luxíq occurred in patients receiving 26 of the 63 patients. These events included mild burning, stinging, or itching at the site of application, and are listed in decreasing order of frequency. Most adverse events were mild in severity except for pruritus, dryness, and stinging.

The most frequent adverse effects associated with the use of Luxíq include mild burning, stinging, or itching at the site of application. These can be limited to the least amount compatible with an effective therapeutic response.

Betamethasone was genotoxic in the formed to evaluate the carcinogenic potential or the effect on the development of interlocking C design, Luxíq, the foam dollop, and VersaFoam-HF is a trademark, and the V logo, the logo of Connetics Corporation.